In mCRPC, a lethal variant of NE prostate cancer, OC2 drives the transition from androgen receptor (AR)-dependent, hormone sensitive prostate cancer to AR-indifferent mCRPC by activating a neural differentiation program (Rotinen et al. 2018). This evidence concerns the gene ONECUT2 and prostate carcinoma.